BCRX Biocryst Pharmaceuticals (BCRX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000882796
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
187
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $315.0K priced
What the filings say about BCRX
Insiders, 180 days
-$696.5K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-07-10
Biocryst Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BIOCRYST PHARMACEUTICALS INC insiders sold a net $696.5K of stock across 56 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 24, 2024.
- The trade is 35.8% of the 31,252 shares held after it.
- 1 other insider sold within 30 days.
- 187 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director McKee Amy E sold about $100.3K of BCRX on May 18, 2026; 1 other insider sold within 30 days and 187 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (1 buy, 7 sales), the last on Mar 16, 2026.
- The trade is 15.6% of the 400,703 shares held after it.
- 1 other insider sold within 30 days.
- 187 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Barnes Alane P sold about $596.2K of BCRX on May 13, 2026; 1 other insider sold within 30 days and 187 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 13, 2025.
- The trade is 76.4% of the 65,352 shares held after it.
- 1 other insider sold within 30 days.
- 187 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HEGGIE THERESA sold about $504.8K of BCRX on Mar 20, 2026; 1 other insider sold within 30 days and 187 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on Dec 22, 2025.
- The trade is 37.4% of the 400,703 shares held after it.
- 1 other insider sold within 30 days.
- 187 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Barnes Alane P sold about $1.4M of BCRX on Mar 16, 2026, the largest insider sale at the company since 2022; 1 other insider sold within 30 days and 187 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (1 buy, 5 sales), the last on Dec 15, 2025.
- The trade is 5.5% of the 398,751 shares held after it.
- No other insider sold within 30 days.
- 187 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Barnes Alane P sold about $166.6K of BCRX on Dec 22, 2025; 187 funds added in the latest 13F quarter.56 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$696.5K over 180 days
below 59% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
187 funds bought in last quarter
more than 88% of Pharma & Biotech
Revenue
+94.1% year over year
more than 83% of Pharma & Biotech
Margin
30.2% net margin
more than 91% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.0% of the float short (float per yahoo 2026-10-27) · 5.8 days to cover · settled 2026-10-15
more than 74% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch BCRX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+12.7%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BCRX: institutional holders (13F)
13F holdings, latest reported quarter
23,893,036 sh
$238.9M
15,827,186 sh
$158.3M
15,191,098 sh
$151.9M
15,096,403 sh
$151.0M
11,364,236 sh
$113.6M
Congress trades in BCRX
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-07-10 · disclosed 56 days later
$1,001 - $15,000
Bought 2025-11-13 · disclosed 32 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BCRX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
BCRX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Biotechnology & Genome ETF
$7.4M position · as of 2026-07-31
2.6%
AMG GW&K Small Cap Growth Fund
$2.9M position · as of 2026-07-31
1.4%
Virtus Biotech Etf
$1.4M position · as of 2026-07-31
1.4%
Virtus NFJ Small-Cap Value Fund
$2.6M position · as of 2026-06-30
1.0%
Janus Henderson Small/Mid Cap Growth Alpha ETF
$9.7M position · as of 2026-07-31
0.9%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$95.8M position · as of 2026-06-30
0.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
16 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
1 active
5
Phase 2
0 active
6
Phase 3
2 active
2
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$13.0M
$1.2M
$5.7M
+5%
+101%
2024
$8.3M
$11.0M
$3.4M
+1%
+56%
2023
$4.8M
-$3.7M
$2.0M
-20%
+44%
2022
$7.0M
$4.0M
$2.6M
+54%
+39%
2021
$7.1M
$17.1M
$4.5M
+86%
+24%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $696.5K sold by insiders over 180 days, 187 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
BCRX financials
Revenue growth
+94.1%
XBRL, annual
Net margin
30.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$940.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BCRX
| FY Dec 2025 | $874.8M |
| FY Dec 2024 | $450.7M |
| FY Dec 2023 | $331.4M |
| FY Dec 2022 | $270.8M |
| FY Dec 2021 | $157.2M |
| Jun 2026 | $218.2M |
| Mar 2026 | $156.4M |
| Dec 2025 | $406.6M |
| Sep 2025 | $159.4M |
| Jun 2025 | $163.4M |
| Mar 2025 | $145.5M |
| Dec 2024 | $131.5M |
| Sep 2024 | $117.1M |
At each fiscal year end
Single quarter
Net margin, TTM
-40.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BCRX
| FY Dec 2025 | +30.2% |
| FY Dec 2024 | -19.7% |
| FY Dec 2023 | -68.4% |
| FY Dec 2022 | -91.2% |
| FY Dec 2021 | -117.1% |
| Jun 2026 | +35.9% |
| Mar 2026 | -461.5% |
| Dec 2025 | +60.5% |
| Sep 2025 | +8.1% |
| Jun 2025 | +3.1% |
| Mar 2025 | +0.0% |
| Dec 2024 | -20.4% |
| Sep 2024 | -12.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$373.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BCRX
| FY Dec 2025 | $344.9M |
| FY Dec 2024 | -$53.1M |
| FY Dec 2023 | -$97.3M |
| FY Dec 2022 | -$163.2M |
| FY Dec 2021 | -$144.5M |
| Jun 2026 | $104.1M |
| Mar 2026 | -$62.2M |
| Dec 2025 | $291.2M |
| Sep 2025 | $40.3M |
| Jun 2025 | $41.1M |
| Mar 2025 | -$27.7M |
| Dec 2024 | -$5.9M |
| Sep 2024 | $8.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity BCRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.95x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt BCRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | -0.17x |
| FY Dec 2023 | -0.31x |
| FY Dec 2022 | -0.70x |
| FY Dec 2021 | -1.04x |
| Jun 2026 | 0.95x |
| Mar 2026 | 0.79x |
| Dec 2025 | n/a |
| Sep 2025 | 0.26x |
| Jun 2025 | 0.07x |
| Mar 2025 | -0.08x |
| Dec 2024 | -0.17x |
| Sep 2024 | -0.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity BCRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-75.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BCRX
| FY Dec 2025 | +52.5% |
| FY Dec 2024 | -17.6% |
| FY Dec 2023 | -42.5% |
| FY Dec 2022 | -43.4% |
| FY Dec 2021 | -39.9% |
| Jun 2026 | -75.8% |
| Mar 2026 | -96.9% |
| Dec 2025 | +52.5% |
| Sep 2025 | -1.9% |
| Jun 2025 | -7.7% |
| Mar 2025 | -11.3% |
| Dec 2024 | -17.6% |
| Sep 2024 | -24.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital BCRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-99.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BCRX
| FY Dec 2025 | +105.2% |
| FY Dec 2024 | -0.7% |
| FY Dec 2023 | -25.6% |
| FY Dec 2022 | -32.0% |
| FY Dec 2021 | -49.8% |
| Jun 2026 | -99.6% |
| Mar 2026 | -125.2% |
| Dec 2025 | +105.2% |
| Sep 2025 | +25.6% |
| Jun 2025 | +17.4% |
| Mar 2025 | +9.6% |
| Dec 2024 | -0.7% |
| Sep 2024 | -10.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing BCRX
| FY Dec 2025 | 6.45x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 6.45x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.3B
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value BCRX
| FY Dec 2025 | $1.6B |
| FY Dec 2024 | $1.8B |
| FY Dec 2023 | $1.4B |
| FY Dec 2022 | $2.1B |
| FY Dec 2021 | $2.1B |
| Jun 2026 | $2.8B |
| Mar 2026 | $2.6B |
| Dec 2025 | $1.6B |
| Sep 2025 | $1.7B |
| Jun 2025 | $2.0B |
| Mar 2025 | $1.8B |
| Dec 2024 | $1.8B |
| Sep 2024 | $1.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+18.0%
TTM free cash flow over market value at close 2026-10-27
FCF yield BCRX
| FY Dec 2025 | +21.0% |
| FY Dec 2024 | -3.4% |
| FY Dec 2023 | -7.9% |
| FY Dec 2022 | -7.6% |
| FY Dec 2021 | -5.8% |
| Jun 2026 | +14.7% |
| Mar 2026 | +13.0% |
| Dec 2025 | +21.0% |
| Sep 2025 | +3.0% |
| Jun 2025 | +0.8% |
| Mar 2025 | -1.7% |
| Dec 2024 | -3.4% |
| Sep 2024 | -3.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing BCRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $874.8M | $450.7M | $331.4M | $270.8M |
| Operating income | $341.0M | -$2.5M | -$103.7M | -$148.4M |
| Net income | $263.9M | -$88.9M | -$226.5M | -$247.1M |
| EPS (diluted) | 1.21 | -0.43 | -1.18 | -1.33 |
| Operating cash flow | $347.4M | -$52.0M | -$95.1M | -$161.8M |
| Cash | $89.7M | $104.7M | $110.6M | $304.8M |
| Long-term debt | $0 | $314.9M | $303.2M | $231.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
BCRX Stock Sonar score 6/7 axes
Find similar shapesCompareBCRX ranks highest on financial health (92nd percentile) and growth (83rd), and lowest on insider conviction (19th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BCRX filings, in plain words
Are Biocryst Pharmaceuticals insiders buying or selling BCRX?
In the 180 days to 2026-10-28, Biocryst Pharmaceuticals insiders were net sellers, a net $696.5K across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded BCRX?
Yes. In the year to 2026-10-28, 1 House member disclosed buying BCRX and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-07-10.
Read the full summary
In the 180 days to 2026-10-28, Biocryst Pharmaceuticals insiders were net sellers of BCRX, a net $696.5K across purchases and sales reported on Form 4 by 2 sellers. In the year to 2026-10-28, 1 member of Congress disclosed buying BCRX and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-07-10. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
